Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Breast Neoplasms 80Neoplasms 14Neoplasm Metastasis 14Brain Neoplasms 9Breast Neoplasms, Male 7Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Stomach Neoplasms 4Urinary Bladder Neoplasms 3Salivary Gland Neoplasms 3Recurrence 3Prostatic Neoplasms 3Inflammatory Breast Neoplasms 3Gallbladder Neoplasms 3Colorectal Neoplasms 3Carcinoma, Squamous Cell 3Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Ovarian Neoplasms 2Glioma 2Glioblastoma 2Ependymoma 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Bile Duct Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Thymoma 1Spinal Cord Neoplasms 1

Interventions

Bevacizumab 10Magnetic Resonance Spectroscopy 9Temozolomide 8Cyclophosphamide 8Etoposide 7X-Rays 6Phantoms, Imaging 6Specimen Handling 5Nuclear Medicine Department, Hospital 5Cisplatin 5Radiotherapy 4Irinotecan 4Filgrastim 4Carboplatin 4Biopsy 4Erlotinib Hydrochloride 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2sargramostim 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2etoposide phosphate 2erdafitinib 2ensartinib 2Vincristine 2Vemurafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Ependymoma × Lapatinib × Clear all
NCT00883688 2020-08-26

Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

M.D. Anderson Cancer Center

Phase 2 Completed
24 enrolled 5 charts
CNS

Brain Neoplasms, Ependymoma, Neuroectodermal Tumors, Primitive, Glioma, Subependymal

NCT00826241 2019-03-22

Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
58 enrolled 11 charts
CNS

Brain Neoplasms, Ependymoma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡